Biotechnology company Seattle Genetics Inc (Nasdaq:SGEN) said on Tuesday that it has triggered a milestone payment from Roche following the European Commission's conditional marketing authorisation for Polivy (polatuzumab vedotin).
The company said Polivy was approved in combination with bendamustine plus MabThera (rituximab) (BR) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. Polivy was granted PRIME (PRIority MEdicines) designation by the EMA for treating R/R DLBCL in 2017.
Polivy, which is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' technology, was developed and is commercialized by Roche/Genentech. The ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and potent cell-killing agents to treat cancer. The technology has been licensed to several companies, including Roche/Genentech and GlaxoSmithKline.
This agreement provides each licensee company with rights to use the technology with antibodies against specified targets. The licensee is responsible for research, product development, manufacturing and commercialization.
Hence, Seattle Genetics is entitled to receive fees, progress-dependent milestone payments and royalties on worldwide net sales of any resulting ADC products.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients